8 results about "Cytokeratin" patented technology

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

The present disclosure relates to aptamers that specifically bind to Cytokeratin 8 (CK8) and / or Cytokeratin 18 (CK18) and their use as biomarkers for the detection of cancer, preferably carcinoma or adenocarcinoma. The present disclosure also relates to an intraoperative surgical pathology method that provides for the rapid identification of cancer cells, in particular carcinoma or adenocarcinoma, in a biological sample.

A TPS CLIA kit comprises an immunoconjugate comprising an alkaline phosphatase conjugated to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to one of the M3 and M21 epitopes of cytokeratin 18, a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to other of the M3 and M21 epitopes, a substrate of alkaline phosphatase and a solid support. The monoclonal antibody, or the antigen-binding fragment thereof, binding specifically to other of the M3 and M21 epitopes is immobilized or is intended to be immobilized to the solid support. The invention also relates to a method for detecting TPS in a sample using the TPS CLIA kit.

Abstract A method for detecting a biological marker in a sample, preferably a biological marker on a cancer cell, the method comprising: (i) contacting the sample with at least one DNA aptamer coupled to a first reagent and wherein the aptamer specifically binds to a first biological marker in the sample to form a first complex; (ii) contacting the first complex of (i) with a second binding agent that specifically binds to the first reagent such that a second complex is formed, wherein the second binding agent is coupled to a reporter molecule; (iii) contacting the second complex (ii) with a substrate for the reporter molecule of the at least one second binding agent; and (iv) detecting the substrate reaction by formation of a reaction product thereby detecting the biological marker in the sample. Biological markers include cytokeratin 8 (CK8), cytokeratin 18 (CK18), human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM). Abstract 41 / 50 FIGURE 40 Frozen section preparation 4 Sample fixation + Wash (10 dips in PBS) DNA aptamer staining DAB Substrate DAB substrate HRP FAM Anti-FITC conjugated with HRP FAM DNA Aptamer conjugated with FAM HRP Frozen section slide / Touch imprint slide / Cytology slide / Direct smear slide Anti-FITC-HRP Wash (10 dips in PBS) DAB Wash (10 dips in PBS) Hematoxylin counter-staining Wash under tap water Cove rs lip DAB brown precipitate at the location of the aptamer B o min 1 min 15 sec 5 min 15 sec 5 min 15 sec 5 min 15 sec 10 sec 1 min 1 min A + Wash (10 dips in PBS) Total time for aptamer-DAB staining: —18 min 4 1 / 5 0 A B 1 0 m i n 1 m i n D A B s u b s t r a t e 1 5 s e c H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n 1 5 s e c D N A A p t a m e r c o n j u g a t e d w i t h F A M 5 m i n D A B W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 020 25 28 36 33 19 D ec 2 02 5 1 9 D e c 2 0 2 5 A B 1 0 m i n F r o z e n s e c t i o n p r e p a r a t i o n 1 m i n S a m p l e f i x a t i o n D A B 2 0 2 5 2 8 3 6 3 3 s u b s t r a t e 1 5 s e c W a s h ( 1 0 d i p s i n P B S ) H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n A n t i - F I T C - H R P T o t a l t i m e f o r 1 5 s e c D N A A p t a m e r W a s h ( 1 0 d i p s i n P B S ) c o n j u g a t e d w i t h F A M 5 m i n D A B s t a i n i n g : ~ 1 8 m i n W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / 1 0 s e c H e m a t o x y l i n C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 0

The application discloses a method and a kit for simultaneously detecting multiple proteins in liver, and belongs to the technical field of medical detection. The target proteins of the method include glutamate amino transferase 1 protein, glutamic transaminase 1 protein, methionine adenosyltransferase 1A protein, glutathione peroxidase 1 protein, cytokeratin 18 and apolipoprotein E. First, the liver tissue to be detected is subjected to pretreatment such as enzymolysis and desalination to obtain a sample solution to be detected, then nanoliter liquid chromatography-tandem mass spectrometry is used to detect six characteristic peptide segments corresponding to the target proteins in the sample solution to be detected, and the content of the corresponding target proteins is calculated according to the content of the characteristic peptide segments. The method is convenient to operate, has good selectivity, high accuracy and high sensitivity, the detection limit reaches the pg / mL level, absolute quantification of the proteins can be realized, and the method has a wide application prospect in the research and development and efficacy evaluation of anti-liver injury drugs.

A lateral flow immunometer 10 includes a sample accommodation portion 20 configured to accommodate a sample; a SERS active particle configured to bind to cytokeratin-18 (K18) in the sample, and a test portion 40 configured to immobilize the SERS active particle that has bound to K18.